Harrison A A, Markou A
Department of Neuropharmacology, The Scripps Research Institute, 10550 North Torrey Pines Rd., La Jolla, CA 92037, USA.
J Pharmacol Exp Ther. 2001 Apr;297(1):316-25.
A discrete-trial current-threshold self-stimulation procedure was used to assess the effects of increased and decreased serotonergic neurotransmission, and 5-HT(1A) receptor activation on brain stimulation reward. Systemic administration of the 5-HT(1A) receptor agonist 8-OH-DPAT had a biphasic effect on brain reward thresholds, without affecting the latency to respond, a measure of performance. The low dose of 8-OH-DPAT (0.03 mg/kg) lowered reward thresholds, whereas higher doses (0.1 and 0.3 mg/kg) elevated thresholds. The 5-HT(1A) receptor antagonist p-MPPI had no effect on brain stimulation behavior, but reversed both the 8-OH-DPAT-induced lowering and elevation of thresholds, indicating that both of these effects of 8-OH-DPAT are mediated through the 5-HT(1A) receptor. Injections of 8-OH-DPAT into the median raphé nucleus also lowered brain reward thresholds, without affecting measures of performance, whereas injections of 8-OH-DPAT into the dorsal raphé nucleus had no effect. A high dose of the selective serotonin reuptake inhibitor fluoxetine (10 mg/kg) elevated reward thresholds and responses latencies, whereas lower doses (2.5 and 5.0 mg/kg) increased response latencies without affecting thresholds. Furthermore, the coadministration of a 5-HT(1A) antagonist, p-MPPI, and a previously ineffective dose of fluoxetine, a drug combination that increases serotonin levels, significantly elevated thresholds. Thus, it is suggested here that the reward-potentiating effects of systemically administered low doses of 8-OH-DPAT may be the result of reduced serotonergic neurotransmission, mediated by activation of 5-HT(1A) somatodendritic autoreceptors in the median, but not the dorsal, raphé nucleus. In conclusion, the present data support the hypothesis that serotonin exerts an inhibitory influence on reward processes.
采用离散式电流阈值自我刺激程序来评估血清素能神经传递增加和减少以及5-羟色胺(5-HT)1A受体激活对脑刺激奖赏的影响。全身性给予5-HT1A受体激动剂8-羟基二丙胺基四氢萘(8-OH-DPAT)对脑奖赏阈值有双相效应,而不影响反应潜伏期(一种行为测量指标)。低剂量的8-OH-DPAT(0.03毫克/千克)降低奖赏阈值,而高剂量(0.1和0.3毫克/千克)则提高阈值。5-HT1A受体拮抗剂对氯苯哌嗪(p-MPPI)对脑刺激行为没有影响,但能逆转8-OH-DPAT引起的阈值降低和升高,表明8-OH-DPAT的这两种效应均通过5-HT1A受体介导。向中缝核注射8-OH-DPAT也会降低脑奖赏阈值,但不影响行为测量指标,而向背侧中缝核注射8-OH-DPAT则没有效果。高剂量的选择性5-羟色胺再摄取抑制剂氟西汀(10毫克/千克)提高奖赏阈值和反应潜伏期,而低剂量(2.5和5.0毫克/千克)增加反应潜伏期但不影响阈值。此外,联合给予5-HT1A拮抗剂p-MPPI和先前无效剂量的氟西汀(一种能增加血清素水平的药物组合)可显著提高阈值。因此,本文认为全身性给予低剂量8-OH-DPAT的奖赏增强效应可能是血清素能神经传递减少的结果,该减少由中缝核而非背侧中缝核中的5-HT1A体树突自身受体激活介导。总之,目前的数据支持血清素对奖赏过程有抑制作用这一假说。